NPR’s Moira Gunn recently interviewed Jeremy Abbate and I on the Scientific American Worldview project. Her interview, broadcast on Tech Nation, is now available at IT Conversations. For more details, you can also see our video interview and the Worldview website.
I often like to read books from technology-based companies outside of the biotechnology space because they can yield insights relevant to biotechnology business development. This book’s attention-grabbing title comes from the author’s experience working as a ranch hand prior to co-founding a computer hardware company.
How to Castrate a Bull describes the growth of NetApp, a disruptive entrant in the data storage business that developed a lower-cost data storage product and fought to gain customers from larger firms while simultaneously proactively defending themselves against other small entrants. The author’s style presents a compelling story, sprinkled with vignettes making analogies to his prior experience in raising cattle. One story, very relevant in any growing company, is the fate of an alpha bull who veers off path when leading a cattle drive: “… sometimes this leader had a tendency to veer off to the side, taking the herd with him. Getting the herd back on track was hard work for the cowboys, so if the lead steer swerved too often, there was no choice but to shoot him in the head.” A sentiment echoed in “When should you fire the founder.”
Another excellent story is when NetApp decided to aim for 100% growth. Hitz explains that failure to out-grow the competition can be detrimental, as a larger, faster-growing, competitor can effectively out-develop, out-sell, and ultimately eliminate a slower-growing company from a market. So, sometimes aggressive growth must be baked into business plans. This requires aggressive sales and R&D efforts to ensure sufficient revenues to support the growth. It also creates growth opportunities for employees. If a manager is promoted and is not able to effectively manage their larger team, an new manager can be hired to replace them and they can try their expanded management role again in a few months as their department continually grows.
The lessons in How to Castrate a Bull are relevant to most biotechnology companies. I recommend it highly for founders, managers, and new employees of growing companies.
*Drugs may be covered by multiple patents
|Tradename||Applicant||Generic Name||Patent Number||Patent Expiration|
|ZOLINZA||Merck||vorinostat||6,087,367||Oct 4, 2011|
|ZORBTIVE||Emd Serono||somatropin recombinant||5,288,703||Oct 7, 2011|
|NUTRESTORE||Emmaus Medcl||glutamine||5,288,703||Oct 7, 2011|
|ATACAND||Astrazeneca||candesartan cilexetil||7,538,133*PED||Oct 18, 2011|
|ATACAND HCT||Astrazeneca||candesartan cilexetil; hydrochlorothiazide||7,538,133*PED||Oct 18, 2011|
|ATACAND||Astrazeneca||candesartan cilexetil||5,705,517*PED||Oct 18, 2011|
|ATACAND HCT||Astrazeneca||candesartan cilexetil; hydrochlorothiazide||5,705,517*PED||Oct 18, 2011|
|ELIGARD||Tolmar Therap||leuprolide acetate||5,324,519||Oct 20, 2011|
|SYMBYAX||Lilly||fluoxetine hydrochloride; olanzapine||5,229,382*PED||Oct 23, 2011|
|ZYPREXA RELPREVV||Eli Lilly Co||olanzapine pamoate||5,229,382*PED||Oct 23, 2011|
|ZYPREXA||Lilly||olanzapine||5,627,178*PED||Oct 23, 2011|
|ZYPREXA||Lilly||olanzapine||5,817,656*PED||Oct 23, 2011|
|ZYPREXA||Lilly||olanzapine||5,817,657*PED||Oct 23, 2011|
|ZYPREXA||Lilly||olanzapine||5,817,655*PED||Oct 23, 2011|
|ZYPREXA||Lilly||olanzapine||5,229,382*PED||Oct 23, 2011|
|ZYPREXA ZYDIS||Lilly||olanzapine||5,229,382*PED||Oct 23, 2011|
This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.
Courtesy of DrugPatentWatch.com
The next DCbiotech meeting will be at the Rennaissance DC Downtown Hotel at 999 Ninth St NW on October 13th 2011. We’ll be meeting in the bar area from 6:30-8:30pm. To facilitate finding the group, you may want to check out my photo on the about page.